7858492

Source:http://linkedlifedata.com/resource/pubmed/id/7858492

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0023487, umls-concept:C0030705, umls-concept:C0040845, umls-concept:C2004454
pubmed:issue	1-2
pubmed:dateCreated	1995-3-20
pubmed:abstractText	All-trans retinoic acid (ATRA) is currently being used as remission induction treatment for acute promyelocytic leukemia (APL). Conventional chemotherapy is added both during and after ATRA treatment, in order to avoid the occurrence of hyperleukocytosis, and to improve the duration of complete remission. In this study we analysed the hematopoietic recovery of 18 consecutive APL patients after standard Idarubicin or Daunorubicin +/- Cytosine-Arabinoside regimens. 9 of the patients were at the onset of the disease, (CHT group) while 9 had been pre-treated with ATRA 45 mg/sqm/day for at least 3 months (ATRA group). 500 PMN/mmc were reached after 20.8 day from the end of treatment in CHT group and after 12.0 days in ATRA group (p = 0.007). Platelets recovery was faster, even though not significantly in ATRA group. Interestingly, PMN recovery in ATRA group was even shorter (p = 0.004) than that obtained in CHT group, after the first course of chemotherapy (treatment in CR vs treatment in CR). If these results are confirmed in a larger study, a protective effect of ATRA on normal residual hemopoiesis should be postulated.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007422
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine, http://linkedlifedata.com/resource/pubmed/chemical/Daunorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Idarubicin, http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Tretinoin
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1042-8194
pubmed:author	pubmed-author:CenacchiAA, pubmed-author:GambergDD, pubmed-author:ManfroiSS, pubmed-author:OttavianiEE, pubmed-author:TosiPP, pubmed-author:TuraSS, pubmed-author:VisaniGG
pubmed:issnType	Print
pubmed:volume	15
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	143-7
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:7858492-Adult, pubmed-meshheading:7858492-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7858492-Cytarabine, pubmed-meshheading:7858492-Daunorubicin, pubmed-meshheading:7858492-Female, pubmed-meshheading:7858492-Hematopoiesis, pubmed-meshheading:7858492-Humans, pubmed-meshheading:7858492-Idarubicin, pubmed-meshheading:7858492-Immunologic Factors, pubmed-meshheading:7858492-Leukemia, Promyelocytic, Acute, pubmed-meshheading:7858492-Leukocyte Count, pubmed-meshheading:7858492-Leukocytosis, pubmed-meshheading:7858492-Male, pubmed-meshheading:7858492-Middle Aged, pubmed-meshheading:7858492-Neutrophils, pubmed-meshheading:7858492-Platelet Count, pubmed-meshheading:7858492-Premedication, pubmed-meshheading:7858492-Remission Induction, pubmed-meshheading:7858492-Salvage Therapy, pubmed-meshheading:7858492-Treatment Outcome, pubmed-meshheading:7858492-Tretinoin
pubmed:year	1994
pubmed:articleTitle	Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia.
pubmed:affiliation	Institute of Hematology, L. e A. Seràgnoli University of Bologna, Italy.
pubmed:publicationType	Journal Article, Clinical Trial